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Abstract. – PURPOSE: The purpose was to
evaluate the efficacy of the treatment of iatro-
genic entropion (IE), in patients affected by pri-
mary open angle glaucoma (POAG), by botu-
linum toxin injections (BTI).
PATIENTS AND METHODS: 20 patients of the
“Glaucoma Center” of the Hospital “Umberto I”
(Rome) were examined. These patients had
POAG and used prostaglandin analogues (PA).
Mean age was 75.5 years old (range 68-83); they
had been suffering from PAOG since 10 years
and were not affected by other relevant systemic
diseases. One to three BTI were made into the
lower orbicularis muscle using a 0.3 G needle
(0.025 to 0.05 units for each injection site).
RESULTS: The results were particularly signifi-
cant in 18 out of 20 patients. Two patients showed
slight improvements. A rating scale ranging from
0 to 6 points (0 corresponded to ‘no effect’ and 6
to the ‘complete’ resolution of the entropion) was
used to evaluate the goals of the treatment. The
average rating was 5.37 points.
CONCLUSIONS: The entropion due to glauco-
ma therapy with PA can be successfully treated
with BTI in the orbicularis muscle, despite offer-
ing temporary therapeutic effects.
Key Words:
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Introduction
Entropion is the turning inward of the eyelid
margin, which is more frequent in the lower eyelid
than in the upper eyelid. This causes a constant
rubbing of the eyelashes on the cornea, which can
lead to irritation, puntate keratitis of the corneal
epithelium, and in chronic cases it can lead to the
ulceration of the cornea and the formation of
corneal pannus. There are several types of entropi-
on with different ethiopathogeneses; the three
main types are congenital, involutional, and cica-
tricial1. Involutional entropion is caused by age-re-
lated deterioration of the elastic fibrous tissue in-
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side the eyelid. Temporary treatment involves the
use of eye drops, application of a patch or thera-
peutic soft contact lens or chemical denervation of
the orbicularis muscle by botulinum toxin injec-
tions (BTI). Instead the eyelid surgery can perma-
nently fix the inward eyelid margin.
Patients affected by glaucoma treated with
prostaglandin analogues (PA) may produce iatro-
genic entropion (IE)1-4. As well known, one of
the adverse side-effects of the substance, is the
increase of conjunctival hyperemia and the
growth and thickening of the eyelashes. In-
creased eyelash growth can develop into trichia-
sis, which increases the risk of entropion in pa-
tients taking this type of drug for a long time.
Such long-term conditions lead to chronic hyper-
aemia, which can evolve into keratitis and
corneal leukoma. In fact, a study carried out by
Bearden et al (2004) also highlighted the correla-
tion between the use of PA in patients affected
by primary open angle glaucoma (POAG) and
the development of trichiasis2.
Botulinum toxin (BT) is produced by bacteria.
This toxin works by blocking nerve communica-
tion at the synapse, which degrades a protein
called SNAP-25, involved in the release of neu-
rotransmitters to nerve endings. The natural tar-
get for the toxin is neuromuscular synapsis and at
this level, the toxin blocks acetylcholine release
and this causes the paralysis of the muscle5.
Clostridium botulinum secretes one of the
most toxic bacterial proteins, targeting the fusion
proteins of synaptic vescicles, which causes
cleavage through zinc metalloprotease activity6.
BT used for therapy began in the 1990s. It was
particularly successful in the treatment of strabis-
mus, blepharospasm, hemifacial spasm, entropi-
on, and other diseases characterized by abnormal
muscle contractions. In addition, it is particularly
effective in the treatment of some types of pain
and against different types of gastrointestinal in-
fection.
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Figure 1. Histogram of data in relationship with frequency.
A. Librando, V. Russo, M. Tarallo, F. Cruciani, S.C. Carlesimo, M. Nebbioso
olution of the entropion. The score was measured
before (t0) and 24 hours after the injection (t1).
Statistical Analysis
The software used was R-project. With Kol-
mogorov-Smirnov test we assumed that the dis-
tribution is reasonably close to a normal one. So
we used the Student’s t test to estimate the range
of variability of the population average. p < 0.05
was considered statistically significant.
Results
The patients were re-examined 24 hours, 15
days and 2 months after the treatment. There was
a further check-up depending on the clinical con-
ditions of each patient. The results were particu-
larly significant in 18 out of 20 patients. Two pa-
tients showed slight improvements. The mean
score before the treatment (t0) was 3.4 (±0.8)
points. The range of variability of the population
average after BTI (t1) was from 4.8 to 5 points.
The confidence level was 95% (Figure 1). In the
patients treated with BT the test values were sta-
tistically significant when compared with the test
values before of the treatment (p < 0.05). These
values suggested the importance of BT in exam-
ined patients (Figure 2A/B).
The maximum effects were observable after
15 days. The average duration of the effect was
about three months. The patients were monitored
by photographs and slit-lamp biomicroscopy to
Several drugs and diseases interfere with the
neuromuscular junction and the effect of BT. To
minimize the risk of resistance induced by anti-
bodies that may develop as a reaction to the tox-
in, it is necessary to adopt certain measures. The
dose used should be the least effective amount
and the injections must be performed at intervals
of more than 3 months. Side effects are rare, but
they may include: ptosis, ectropion, diplopia,
bruising, and headaches5-8.
Our purpose was to evaluate the efficacy of
the treatment of entropion, iatrogenic related,
through BTI to obtain temporary chemical dener-
vation of the orbicularis muscle in POAG pa-
tients treated with PA.
Patients and Methods
20 patients of the “Glaucoma Center” of “Um-
berto I” Hospital (Rome) were examined. Mean
age was 75.5 years old (range 68-83); they had
been suffering from POAG under therapeutic
control with PA (one drop once a day in the
evening) from at least 2 years. The study was
conducted in full accordance with the Declara-
tion of Helsinki. All subjects were informed and
consented to the use of their data in this study.
The protocol was approved by the Ethical Com-
mittee, Sapienza University, Rome, Italy.
The patients enrolled in the research were not
affected by other relevant systemic diseases.
Eyelids were disinfected; then from one to three
injections of BT were made with a 0.3 G needle,
into the lower orbicularis muscle, immediately
below the eyelid margin, in the medial- lateral-
and middle-third regions. One hundred units of
type A “Botox” (Allergan Pharmaceuticals Ire-
land, Castlebar Road, Westport, County Mayo,
Ireland) were injected. We diluted the soluble
powder with a sterile sodium chloride solution 9
mg/ml (0.9%). An extra 2.5 ml of sodium chlo-
ride was then added, thus obtaining 6.25 total
units of the medicine, to be used on our 20 sam-
ple patients. The dose of the drug varied from
0.025 to 0.05 units for each injection site, there-
fore it was much lower than the dose recom-
mended in the medical leaflet for treating ble-
pharospasm, which in fact prescribes 1.25-2.5
units for each injection site.
To evaluate the difference between the stage of
the disease before and after the treatment a rating
scale ranging from 0 to 6 points was used; 0 corre-
sponded to ‘no effect’ and 6 to the ‘complete’ res-
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Figure 2. Photographs before and after treatment with botu-
linum (A). Rating scale from 0 to 6 where 0 corresponded to
“no effect” and 6 to the ‘complete’ resolution of entropion (B).
assess the evolution of their clinical condition
(Figure 2A/B). The dose of drug used was effec-
tive and reduced the risk of ectropion and other
side effects.
Discussion
We have focused on the effectiveness of entro-
pion treatment by BTI into the orbicularis mus-
cle, in patients affected by POAG undergoing PA
therapy.
In 1988 Clarke et al9 carried out a study using
BT to treat senile entropion in 12 patients. The pa-
tients underwent BTI in the preseptal part of the
orbicularis muscle. There were notable effects of a
temporary improvement of the symptoms in 10
patients. On average the effects lasted 14.8 weeks,
while in our experiment we report a lasting effect
of 12 weeks. Clarke et al. conclude that in the
sample selection of patients, BT not only offers a
good resolution to the clinical problem, it also of-
fers a treatment which can be performed easily.
However it is necessary to point out that surgery
provides the longest-lasting results.
Deka et al10, in a prospective study, evaluated
the efficiency of BT as temporary treatment for
senile entropion and congenital lower lid entropi-
on. Twenty patients were examined: 17 had senile
entropion and 3 children had congenital entropion.
The patients were treated with BTI in the preseptal
portion of the lower eyelid orbicularis muscle, re-
sulting in a visible improvement of their condition
within 8-26 weeks. The authors claimed the pro-
cedure was simple to perform, which we confirm
from our own experience. The treatment proved
effective for both types of entropion.
More recently11 Winterhoff et al. reported a
case study of treatment on a 74 year old man suf-
fering from dementia who had spastic entropion.
The patient was successfully treated with BTI to
the lower eyelid, in this way avoiding surgery.
Similarly to our own experience, the authors ac-
knowledge the importance of symptomatic treat-
ment, comprising BT, as an alternative therapy to
surgery in patients at risk.
Two medical research groups assessed the ef-
fect of BT in two famous products: Botox® and
Dysport®. Badamy et al12 observed the effective-
ness of Dysport® in patients treated with Botox®
for blepharospasm and hemifacial spasm, but
which had no effect. They claimed the ineffec-
tiveness was due to the formation of specific an-
tibodies against BT, which occurs more frequent-
ly in long-term therapies. Botox® and Dysport®
are both serotype A BTs, but they seems to have
different biological activity.
Whereas, Bentivoglio et al13 compared the
clinical conditions and long-term results of 128
patients with blepharospasm treated with the
most widely used brands of BT, namely Botox®
and Dysport® in the last 15 years. They treated
1341 patients, 1009 of whom were injected with
Botox® and 332 with Dysport®. The Botox®
dosage was 0.40 units, whereas the Dysport® one
was 0.16. These quantities were increased over
time. Both drugs proved effective and safe in the
treatment of blepharospasm.
However, on the contrary, in our study we
were able to obtain satisfactory results with very
small quantities of Botox® (a maximum of 0.15
units per patient).
In contrast Arat et al14, in their study claimed
that the reduction of tear production caused by
BTI, with the aesthetic aim of removing periocu-
lar wrinkles, is a possible complication. The BT
dosage used was two injections of 10 units for
each side.
For this reason, it is important that patients
should be informed about the possible conse-
quences of this type of treatment, even though
they are rare and often temporary.
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The disadvantage of the treatment using BT is
its temporary nature, lacking any definite resolu-
tion, implying life-long therapy for the patients.
Such conditions are undesirable, both for the pa-
tient and for the very high costs incurred by the
public health system. BT is considered safe and
effective. However, it is crucial to understand its
mechanism of action and the way it interacts
with other substances in order to standardize the
application techniques, optimize the effects and
maximize its therapeutic potential.
Conclusions
The entropion due to glaucoma therapy with
PA seems to be successfully treated by BTI in
the orbicularis muscle with the minimum effec-
tive dosage. However, it seems to offer tempo-
rary therapeutic effects.
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